Influence of liver nonparenchymal cell infusion combined with cyclosporin A on rejection of rat small bowel transplantation.
OBJECTIVE
To investigate the effect of liver nonparenchymal cell infusion combined with cyclosporin A (CsA) on rejection of heterostrain rat small bowel transplantation.


METHODS
The liver nonparenchymal cell suspension was prepared by density gradient centrifugation method with Percoll centrifugal solution. Heterotopic small bowel transplantation was performed. Then the rats were divided into four groups. Group one: homogenic transplantation (F344/N-F344/N), group two: allotransplantation (F344/N-Wistar), group three: allotransplantation (F344/N-Wistar) + CsA, with CsA 10 mg/kg(-1)/d(-1) after transplantation, group four: allotransplantation + CsA (F344/N-Wistar) + liver nonparenchymal cell infusion + CsA (F344/N-Wistar), in which recipient Wistar rats had been injected with 2x10(8) F344/N liver nonparenchymal cells 20 days before transplantation, and treated with CsA after transplantation. Finally, the survival time after small bowel transplantation, gross and histopathological examination, and IL-2 levels in serum were observed.


RESULTS
The survival time after small bowel transplantation was 7.14 +/- 0.33 d, 16.32 +/- 0.41 d and 31.41 +/- 0.74 d in group 2, 3, and 4, respectively. The survival time was significant longer (P<0.01) in group 4. The gross and histopathological examination showed that the rejection degree in group 4 was lower than those in groups 2 and 3. Serum IL-2 level in group 4 was also lower than those in groups 2 and 3 (P<0.01).


CONCLUSIONS
Liver nonparenchymal cell infusion combined with CsA can prolong the survival time of rat small bowel transplantation, and the anti-rejection effect is good.
Yang
Yan-Ling
YL
Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, Shaanxi Province, China.
Li
Ji-Peng
JP
Dou
Ke-Feng
KF
Li
Kai-Zong
KZ
D000818:Animals; D017690:Cell Transplantation / Q000379:methods / Q000401:mortality; D016572:Cyclosporine / Q000627:therapeutic use*; D006085:Graft Survival / Q000502:physiology*; D007165:Immunosuppression Therapy / Q000379:methods; D007421:Intestine, Small / Q000637:transplantation*; D008297:Male; D051381:Rats; D011916:Rats, Inbred F344; D017208:Rats, Wistar; D016019:Survival Analysis; D014184:Transplantation, Homologous / Q000276:immunology / Q000379:methods* / Q000401:mortality
D016572:Cyclosporine